Literature DB >> 10903263

Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.

D H Hamer1.   

Abstract

Gram-negative bacilli including multidrug-resistant (MDR) Pseudomonas aeruginosa are responsible for a significant proportion of episodes of nosocomial pneumonia. Since the development of new antibiotics with activity against gram-negative organisms has not kept pace with the increase in prevalence of MDR pathogens, there has been renewed interest in antimicrobial agents that had previously been used but had been abandoned because of toxic side effects. This report describes three patients with nosocomial pneumonia or tracheobronchitis due to multiresistant strains of P. aeruginosa for whom aerosolized colistin proved beneficial as supplemental therapy. Aerosolized colistin merits further consideration as a therapeutic intervention for patients with pulmonary infections due to MDR P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903263     DOI: 10.1164/ajrccm.162.1.9910071

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

1.  Nosocomial Pneumonia: More Than Just Ventilator-Associated.

Authors:  Joseph R. Lentino
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

2.  Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 3.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

Review 4.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

Review 5.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

7.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

8.  Inhaled antimicrobial therapies for respiratory infections.

Authors:  Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

9.  Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review.

Authors:  Istemi Han Celik; Serife Suna Oguz; Gamze Demirel; Omer Erdeve; Ugur Dilmen
Journal:  Eur J Pediatr       Date:  2011-08-02       Impact factor: 3.183

10.  Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock.

Authors:  Suresh Ramasubban; Ayanava Majumdar; Purnendu Sekhar Das
Journal:  Indian J Crit Care Med       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.